{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.4","upperLimit":"30.7","value":"21.1"},{"groupId":"OG001","lowerLimit":"19.5","upperLimit":"35.6","value":"24.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"153"}],"units":"Participants"}],"description":"MaHR was defined by either CHR or no evidence of leukemia NEL. CHR was defined as: WBC ≤ ULN; ANC ≥ 1,000/mm\\^3; - platelets ≥ 100,000/mm\\^3; - no blasts or promyelocytes in PB; BM blasts ≤ 5%; \\< 5% myelocytes plus metamyelocytes in PB; basophils in PB \\< 20%; no extra-medullar involvement (including no hepatomegaly or splenomegaly). NEL defined by the same criteria as CHR except that platelets and ANC had to satisfy at least one of the following (note that both lower limits had to be satisfied): platelets ≥ 20,000/mm\\^3 and \\< 100,000/mm\\^3; ANC \\> 500/mm\\^3 and \\<1,000/mm\\^3. Median duration was measured in months.","dispersionType":"95% Confidence Interval","groups":[{"description":"Dasatinib was administered orally at a dose of 140 mg once a day (QD) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant.","id":"OG000","title":"Dasatinib 140 mg QD"},{"description":"Dasatinib was administered orally at a dose of 70 mg twice a day (BID) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant..","id":"OG001","title":"Dasatinib 70 mg BID"}],"paramType":"MEDIAN","populationDescription":"Participants who achieved a MaHR during the study.","reportingStatus":"POSTED","timeFrame":"Day 1 up to 5 years","title":"Median Duration of a Major Hematologic Response (MaHR) in Those Participants Who Achieved a MaHR During the Study","type":"SECONDARY","unitOfMeasure":"Months"}